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Purpose: Biomarkers as common data elements (CDEs) are important for the
characterization of biobehavioral symptoms given that once a biologic moder-
ator or mediator is identified, biologically based strategies can be investigated
for treatment efforts. Just as a symptom inventory reflects a symptom expe-
rience, a biomarker is an indicator of the symptom, though not the symptom
per se. The purposes of this position paper are to (a) identify a “minimum set”
of biomarkers for consideration as CDEs in symptom and self-management
science, specifically biochemical biomarkers; (b) evaluate the benefits and lim-
itations of such a limited array of biomarkers with implications for symptom
science; (c) propose a strategy for the collection of the endorsed minimum set
of biologic samples to be employed as CDEs for symptom science; and (d) con-
ceptualize this minimum set of biomarkers consistent with National Institute
of Nursing Research (NINR) symptoms of fatigue, depression, cognition, pain,
and sleep disturbance.
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Design and Methods: From May 2016 through January 2017, a working
group consisting of a subset of the Directors of the NINR Centers of Excel-
lence funded by P20 or P30 mechanisms and NINR staff met bimonthly via
telephone to develop this position paper suggesting the addition of biomark-
ers as CDEs. The full group of Directors reviewed drafts, provided critiques
and suggestions, recommended the minimum set of biomarkers, and approved
the completed document. Best practices for selecting, identifying, and using
biological CDEs as well as challenges to the use of biological CDEs for symp-
tom and self-management science are described. Current platforms for sample
outcome sharing are presented. Finally, biological CDEs for symptom and self-
management science are proposed along with implications for future research
and use of CDEs in these areas.
Findings: The recommended minimum set of biomarker CDEs include
pro- and anti-inflammatory cytokines, a hypothalamic-pituitary-adrenal axis
marker, cortisol, the neuropeptide brain-derived neurotrophic factor, and DNA
polymorphisms.
Conclusions: It is anticipated that this minimum set of biomarker CDEs will
be refined as knowledge regarding biologic mechanisms underlying symptom
and self-management science further develop. The incorporation of biologi-
cal CDEs may provide insights into mechanisms of symptoms, effectiveness
of proposed interventions, and applicability of chosen theoretical frameworks.
Similarly, as for the previously suggested NINR CDEs for behavioral symptoms
and self-management of chronic conditions, biological CDEs offer the potential
for collaborative efforts that will strengthen symptom and self-management
science.
Clinical Relevance: The use of biomarker CDEs in biobehavioral symp-
toms research will facilitate the reproducibility and generalizability of research
findings and benefit symptom and self-management science.
This position paper is the third in a series, authored by
the Directors of National Institute of Nursing Research
(NINR) Centers of Excellence (P30) and Exploratory Cen-
ters (P20) that focus upon advancing symptom and self-
management science through the utilization of common
data elements (CDEs). The goal is to conceptually define,
operationalize, and measure outcomes across research
studies. The first paper focused upon the identification
and development of CDEs for self-reported symptoms,
their use, data-sharing platforms, benefits and challenges
of CDEs in symptom science, and future research implica-
tions of CDEs for symptom science (Redeker et al., 2015).
The second paper focused upon CDEs for research ad-
dressing self-management of chronic conditions (Moore
et al., 2016). This third paper proposes biochemical
biomarkers as CDEs for symptom and self-management
science as a means by which to integrate biological
with behavioral characterizations of symptoms and self-
management. Once biological mechanisms for symptoms
can be discerned, treatment efforts can focus on these
biological mediators and moderators. This is an important
endeavor given the National Institutes of Health (NIH)
NINR strategic emphasis on symptom science. In 1998,
the NIH Biomarkers Definitions Working Group defined a
biomarker as “a characteristic that is objectively measured
and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses
to a therapeutic intervention” (Strimbu & Tavel, 2010,
p. 463).
The purposes of this paper are to (a) identify a
minimum set of biomarkers for consideration as CDEs
in symptom and self-management science, (b) eval-
uate the benefits and limitations of such a limited
array of biomarkers with implications for symptom
science, (c) propose a strategy for the collection of
the endorsed minimum set of biologic samples to be
employed as CDEs for symptom science, and (d) con-
ceptualize this minimum set of biomarkers consistent
with NINR symptoms of fatigue, depression, cognition,
pain, and sleep disturbance and aligned with a frame-
work of the biobehavioral characterization of sickness
behavior, a longstanding heuristic model that is of
reasonable complexity with regard to brain and behavior
interactions.
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Best Practices for Selecting and Using
Biological Common Data Elements
Several principles warrant consideration when plan-
ning for the integration of biological and behavioral
outcomes in symptom and self-management science and
more specific recommendations of biomarkers as CDEs.
The first principle is analytic validity, that is, determining
whether specific biomarkers are consistently reflective
of a given symptom such that changes in biomarker
levels are accompanied by changes in report of that
symptom. Depending upon the approach, it would also
be theoretically and conceptually important to evaluate
whether interventions that alter symptoms also alter
biomarker levels in a consistent way. If a biomarker is hy-
pothesized to underlie the symptom or self-management
phenomenon under study, it should be altered by the
intervention if the biomarker mediates the symptom.
Adding to the complexity of these relationships, how-
ever, is the recognition that individual biomarkers may
mediate or moderate multiple pathways or multiple
biomarkers may impact a single pathway (Miaskowski,
2016). The second principle is the quality of the evidence
for each biomarker as it relates to the behavioral phe-
nomenon, particularly with regard to the consistency
of the “pairing” between behavioral and biomarker
findings. Meta-analytic and rigorous experimental design
are the most desirable approaches for building scientific
support for these relationships. The third principle relates
to our ability to measure biomarkers with precision,
sensitivity, and specificity in any appropriately equipped
laboratory. This principle also assumes appropriate
sample collection, processing, and preservation before
measurement, assuring sample quality as well as admin-
istrative precision and appropriate attribution of sample
to participant. Continuing validation of biomarker and
behavioral relationships contributes to their usefulness as
CDEs. These three principles guided the deliberations of
the writing team throughout the 8 months of meetings
during which the recommendations for biomarker inclu-
sion in symptom science were developed and consensus
was reached. Compared to self-management science,
there is a much greater body of literature supporting
biomarkers for symptom science.
Sickness behavior offers an exemplar of relationships
among a constellation of symptoms that accompany
infection in both humans and animals. Symptoms
including fatigue, sleep disturbance, reduced appetite,
anhedonia, fever, myalgia, depressive symptoms, and
pain emerge along with the immune activation mounted
in response to the infection (Dantzer, 2001; McCusker
& Kelley, 2013). Although it remains unclear exactly
how a localized or systemic inflammatory response is
transmitted to the central nervous system and initiates
the sickness symptom response (Poon, Ho, Chiu, Wong,
& Chang, 2015), studies in rats and mice have demon-
strated that this symptom constellation is caused by
increased pro-inflammatory cytokine levels in the brain.
Mechanisms by which this may occur are several, includ-
ing (a) entry of peripherally elevated cytokines into the
brain through the blood–brain barrier; (b) activation of
the afferent arm of the vagus nerve, which then conveys
an inflammatory signal to the brain; or (c) cytokine
production in the brain as a consequence of the immune
activation in response to the infection (Poon et al.,
2015). Pro-inflammatory tumor necrosis factor alpha
(TNF-α) or interleukin (IL)-1 beta (IL-1β) are necessary
for the development of sickness behaviors (McCusker
& Kelley, 2013). Human experimental endotoxemia via
the administration of small doses of lipopolysaccharide
(LPS), cell wall components of Gram-negative bacteria,
is a strategy to study inflammation-induced changes
in cognition and motivation. The exemplar of sickness
behavior is consistent with the NIH Symptom Science
Model (Cashion & Grady, 2015) that describes how
complex symptoms reflect the outcome of an individual’s
phenotype, including biological, genetic, psychosocial,
and behavioral factors. Sickness behavior likewise
reflects a constellation of symptoms that arise in an in-
dividual based on an inflammatory phenotype, overlaid
on personal factors. As such, sickness behavior offers a
mechanistic framework to better predict, track, and target
the biology underlying individual symptom experiences.
Identifying and Selecting Biological
Common Data Elements
Identifying and selecting biomarkers to include in
a given research study ultimately depends upon the
research question and the evidence in the literature. For
nurse scientists, such biomarkers might include those
known or suspected of playing a role in mechanistic
pathways associated with symptoms or symptom clusters
of acute or chronic illness, or stress. Within the sick-
ness symptom framework described above, biomarkers
associated with inflammation are often a choice for
study inclusion given the reported associations be-
tween inflammation and fatigue (Kim, Miller, Stefanek,
& Miller, 2015; Louati & Berenbaum, 2015; Morris,
Berk, Walder, & Maes, 2015), pain (DeVon, Piano,
Rosenfeld, & Hoppensteadt, 2014; Diatchenko, Nackley,
Slade, Fillingim, & Maixner, 2006; Ji, Chamessian, &
Zhang, 2016; Klyne, Barbe, & Hodges, 2017), depressive
symptoms (Cai, Huang, & Hao, 2015; Huang & Sheng,
2010; Kiecolt-Glaser, Derry, & Faqundes, 2015; Miller &
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Raison, 2016) cognitive function (Harden, Kent, Pittman,
& Roth, 2015), and sleep disturbance (Harden et al.,
2015; Kamath, Prpich, & Jillani, 2015).
Biomarkers associated with exposure to acute or
chronic stress are also often measured in nursing sci-
ence protocols, reflecting the recognition by many that
emotional, physical, neighborhood, financial, relational,
and societal stressors have a significant impact on health
and well-being. Studies focusing upon self-management
of symptoms and including biomarkers have been
conducted, but are less common in the literature. For
example, an abbreviated progressive muscle relaxation
stress-management technique yielded reductions in
psychological stress measures and diurnal cortisol se-
cretion among first year university students (Chellew,
Evans, Fornes-Vives, Pérez, & Garcia-Banda, 2015);
and a 10-week guided imagery intervention in women
with fibromyalgia improved self-reported self-efficacy
and reduced perceived stress, fatigue, pain severity, and
depressive symptoms compared to usual care, although
immune biomarkers were not significantly impacted
(Menzies, Lyon, Elswick, McCain, & Gray, 2014).
Biomarkers that are more specifically linked to a given
symptom or condition are also included in many research
protocols. For example, investigators may measure spe-
cific hormones or neuroimaging biomarkers to explore
mechanisms, risks, or treatments for hyperalgesia (Matic,
van den Bosch, de Wildt, Tibboel, & van Schalk, 2016;
Maurer, Lissounov, Knezevic, Candido, & Knezevic,
2016). Likewise, measuring changes in levels of brain-
derived neurotrophic factor (BDNF), a peptide involved
in neurogenesis, may be useful to evaluate how inter-
ventions such as exercise improve cognition (Meeusen,
2014), which, in turn, may improve self-management.
Immune and Inflammatory Markers
The immune response includes both innate and
specific reactions driven by the increased production
of white blood cells (WBCs) and the secretion from
those cells of chemical products, including cytokines
(Paul, 2013). Cytokines, defined as small peptides se-
creted by WBCs drawn to sites of injury or infection
(Dinarello, 2007), provide communication between
different types of WBCs. By this means, cytokines direct
the immune and inflammatory response, and play a key
role in host defense. Since normal or abnormal levels
of cytokines remain imprecisely defined, cytokine levels
are typically compared between groups or within one
group before and after an event or intervention. Often
cytokines are grouped as pro- or anti-inflammatory,
or as contributing to the innate or active immune
response.
The innate immune response involves the secretion of
pro-inflammatory cytokines, including IL-1β, IL-2, IL-6,
interferon-gamma (IFN-γ ), and TNF-α, from type 1 T
helper (Th1) lymphocyte activation of peripheral blood
mononuclear cells, including macrophages, monocytes,
and natural killer cells (Dinarello, 2007). Elevated levels
of pro-inflammatory cytokines initiate cell-mediated and
phagocytic-protective responses, and have been linked to
the development of sickness symptoms (Dantzer & Kel-
ley, 2007) as well as a variety of chronic and acute disease
states (Godbout & Glaser, 2006; Wang et al., 2014). Other
cytokines, including IL-4, IL-10, and IL-13, are gener-
ally considered anti-inflammatory and are responsible for
various aspects of the specific immune response such as
antibody production and eosinophil accumulation. The
release of anti-inflammatory cytokines is primarily under
the control of a different subset of T lymphocytes called
T helper 2 (Th2) cells. Th2 responses are characteristic of
humoral, or B cell, immunity. These cytokines are consid-
ered anti-inflammatory to a large extent because of their
ability to inhibit the production of the pro-inflammatory
cytokine transcription factor nuclear factor-kappa beta
(NFkappaB), thereby suppressing pro-inflammatory cy-
tokine gene activation and cytokine production. Measur-
ing levels of pro- and anti-inflammatory cytokines, or the
ratio of pro- to anti-inflammatory cytokines, provides a
sensitive measure of cytokine equilibrium or disequilib-
rium (Petrovsky, 2001).
Cytokines are typically measured in plasma or serum
samples collected from a study participant using sterile
technique and processed according to specific protocols.
Cytokine levels have also been reported in urine and
saliva.
Markers of Stress
Biomarkers of acute and chronic stress of in-
terest to nursing scientists often include the hor-
mones of the hypothalamic-pituitary-adrenal (HPA) axis:
corticotropin-releasing hormone (CRH), adrenal corti-
cotropin hormone (ACTH), and cortisol. Elevation in any
of the HPA axis hormones may occur with exposure to
acute or chronic stress, and each has been associated
with sickness symptoms, including depressive symptoms
(Raison & Miller, 2013), heightened pain sensitivity and
sleep disturbance (Dantzer, O’Connor, Freund, Johnson,
& Kelley, 2008). Moreover, given the accumulating evi-
dence that chronic stress interferes with cognitive func-
tioning, exposure to chronic stress may interfere with an
individual’s ability to self-manage his or her health or
a caregiver’s ability to be an effective contributor to the
self-management of another’s health (Allen et al., 2017;
Arnsten, 2015). Collection and analysis of plasma, serum,
Journal of Nursing Scholarship, 2018; 50:3, 276–286. 279
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or cerebral spinal fluid levels of CRH and ACTH require
strict consideration of sample collection methods, sam-
ple processing, and bioassay techniques. Cortisol levels
are easily measured in plasma, serum, hair, or saliva, but
consideration of free (salivary) versus bound (blood) cor-
tisol, and of the strong diurnal rhythm of all HPA axis
hormones, must be considered when planning studies in-
volving these biomarkers (Segerstrom, Boggero, Smith,
& Sephton, 2014). If serum or plasma samples are cho-
sen, separation of free versus bound cortisol or concur-
rent measurement of cortisol-binding globulin would be
required.
Also, frequently studied when considering bio-
logic responses to chronic stress is the interaction
between the inflammatory response and cortisol levels.
Pro-inflammatory cytokines, released in response to
infection, trauma, or psychological stress, are potent
stimulators of the HPA axis, leading to increased lev-
els of circulating cortisol (Petrovsky, 2001; Steptoe,
Hamer, & Chida, 2007). Circulating cortisol binds to
the cytoplasmic glucocorticoid receptors of WBCs, and
once bound, the cortisol-receptor complex translocates
to the nucleus where it inhibits the production of
key cytokine transcription factors, effectively halting
pro-inflammatory cytokine production (Pace & Miller,
2009; Ratman et al., 2013). This cytokine-glucocorticoid
negative feedback cycle is an important homeostatic
mechanism by which the inflammatory response is
controlled. This negative feedback cycle can be disrupted
in persons exposed to chronic stress due to a decreased
sensitivity of the glucocorticoid receptor to chronically
elevated cortisol, contributing to overproduction or
dysregulated production of pro-inflammatory cytokines
(Corwin et al., 2013; Pace & Miller, 2009). Biomark-
ers measured in studies of glucocorticoid resistance
may include cortisol and pro-inflammatory cytokine
ratios or levels of cytokine transcription factors such as
NFkappaB. NFkappaB can be measured in blood samples
using enzyme-linked immunosorbent assay (ELISA)
kits.
Other Biomarkers of Frequent Interest
to Nursing Science
BDNF is a peptide required for brain neurogenesis, in-
cluding axonal growth and synaptic plasticity. BDNF is
linked to fetal and infant neurodevelopment, as well as
memory, neuronal plasticity, cognition, and affect across
the lifespan (Angelucci, Brenè, & Mathè, 2005). The
BDNF locus is on chromosome 11, and a relatively com-
mon single nucleotide polymorphism within the BDNF
gene, Val66met, has been linked to the development
of depressive symptoms in response to stress exposure
(Gatt et al., 2009). Serum BDNF protein levels vary de-
pending upon genotype (Lang, Hellweg, Sander, & Gal-
linat, 2009), and have been reported to increase with
exercise in a sex-dependent manner (Szuhany, Bugatti,
& Otto, 2015), but decrease with chronic stress (Gatt
et al., 2009), inflammation (Tong et al., 2012), and aging
(Patterson, 2015). Compared to a control group, older
heart failure patients undergoing a cognitive training
intervention, Brain Fitness, improved working memory
and exhibited increased BDNF protein levels (Pressler
et al., 2015). Recently, epigenetic changes in the BDNF
gene were identified as possible links between environ-
mental stressors and psychological disorders (Mitchel-
more & Gede, 2014). BDNF upregulation in the spinal
dorsal horn following noxious stimulation plays an im-
portant role in the development of central sensitization,
a maladaptive neuroplasticity that drives long-term and
persistent pain (Merighi et al., 2008; Nijs et al., 2015;
Smith, 2014). As a biomarker in nursing research studies,
BDNF may be measured before and after an intervention
such as exercise, or in patients with chronic disease, or
may be compared across populations. BDNF protein can
be measured using an ELISA method, and BDNF mRNA
can be measured via quantitative polymerase chain reac-
tion (qPCR) in serum, leukocytes extracted from serum,
or plasma samples. The decision of how and when to
measure BDNF, however, can be complex, as there are
other factors, including time of blood draw, sex, blood
storage time, food intake prior to blood draw, smok-
ing status, and other sociodemographic factors, that are
critically important for consideration prior to designing
the experiment (for review see Cattaneo, Cattane, Begni,
Pariante, & Riva, 2016).
Another category of biomarkers frequently evaluated
in nursing research is genetic polymorphisms. As with
BDNF, genetic polymorphisms have been identified
that influence whether and to what degree an indi-
vidual might experience a particular symptom, and
thus their presence or absence may be considered a
risk or protective factor for symptom development. For
example, polymorphisms of genes coding for cytokines
have been linked to increased risk of fatigue (Lee, Gay,
Lerdal, Pullinger, & Aouizerat, 2014), sleep disturbance
(Miaskowski et al., 2012), depressive symptoms (Kim
et al., 2013; Tartter, Hammen, Bower, Brennan, & Cole,
2015), and pain hypersensitivity among cancer patients
(Oliveira et al., 2014; Shi et al., 2015). Other studies have
linked genetic polymorphisms of the BDNF gene to pain
and depressive symptoms in older adults (Klinedinst,
Resnick, Yerges-Armstrong, & Dorsey, 2015), to dysmen-
orrhea (Lee et al., 2014), and to chronic musculoskeletal
pain (Generaal et al., 2016). These and similar examples
280 Journal of Nursing Scholarship, 2018; 50:3, 276–286.
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emphasize the range of clinically relevant research
studies utilizing genetic biomarkers.
Measuring genetic polymorphisms requires first isolat-
ing the DNA and then sequencing the samples using PCR.
Each of these steps requires careful consideration of the
sample source (whole blood or serum) and access to DNA
sequencing technology.
Platforms for Sample Outcome Sharing
Identifying and selecting biomarkers in symptom
and self-management research is extremely important;
however, equally important are electronic platforms by
which stored sample sets can be explored and leveraged,
and expert collaborators can be identified to enhance
research.
NINR center collaboration involves identifying and
leveraging opportunities within universities and clinical
centers and potentially across other NIH centers or other
universities (Dorsey et al., 2014). Big data science is an
exploding field in which data sharing and collaboration
have become the norm, and awareness of where to find
these opportunities is key. There are many informative
and comprehensive web-based platforms that are now
available for obtaining biospecimens or datasets, or find-
ing other scientists with whom to collaborate in utilizing
profiling platforms, research collaboration platforms, and
biorepository platforms (Redeker et al., 2015). Table S1
offers examples of these platforms.
Sample Quality and Administrative
Oversight
The ability to utilize biological CDEs across studies
depends upon the quality of the samples and the rigor by
which they are collected, maintained, and assayed. Key
to ensuring sample quality is consideration of, and strict
adherence to, the methods by which each sample is col-
lected. This may include time of day if the biomarker has
a diurnal rhythm, may require subjects to be fasting, or
may or may not require that a sample be kept on ice prior
to processing and may or may not need to adhere to cer-
tain time constraints. For many types of biological sample
collections, specific tubes with additives may be required
(e.g., Tempus Blood RNA tube [Fisher or Paxgene Blood
RNA tubes would both be viable tubes for measurement
of DNA]). The sample may need to be centrifuged prior
to aliqoting and freezing. In some cases, a sample may
need to be incubated at a certain temperature, for a
specified period of time. Similar detail will be required
to ensure consistency in assay procedures. For example,
if a commercial kit will be used in assaying a particular
analyte, the same kit is recommended to be used by other
investigators if possible, and details on all procedures
need to be consistent across laboratories. These and other
considerations must be discussed a priori, based on best
practices from the literature. It will also be essential
that collected samples are cataloged as they come into a
laboratory and as they are assayed there or sent to other
laboratories. Tracing the course of a sample from its
collection, to processing, to storage, to assay or transport
also contributes to the scientific rigor, transparency,
and reproducibility of the data generated from that
sample.
Challenges to the Use of Biological
Common Data Elements for Symptom
and Self-Management Science
Challenges in selecting and using biomarkers for symp-
tom and self-management science include identifying and
selecting relevant biomarkers that are components of the
biological pathways of interest, and careful operational-
ization of symptom and self-management phenotypes,
including multidimensionality, clustering, and temporal
patterning.
Multiple biological pathways may contribute to symp-
toms and self-management, and each of these may have
multiple biomarkers. Examples as described above may
include the HPA axis stress pathways, inflammatory
pathways, and sickness behavior. In some cases, little
may be known about underlying pathways, or competing
explanations may need to be tested. Understanding of
putative pathways is needed to identify relevant biomark-
ers of interest. In the event that multiple biomarkers
are examined, this may be associated with significant
cost.
Distinct phenotypes of symptoms and the impact of
self-management interventions must be selected with
care to sensitively detect associations of biomarkers
with these phenomena or to examine the effects of
symptom and self-management interventions on biol-
ogy. Challenges to phenotyping symptoms and self-
management include the wide variety of operational
definitions of symptom and self-management concepts;
the inherently multidimensional, temporal, and percep-
tual characteristics of these phenomena; overlap and
multicollinearity among symptoms; cultural, linguistic,
developmental, and cognitive differences in the ex-
pression of these self-reported phenomena; and their
meanings to respondents. For example, depressive
symptoms have cognitive and somatic dimensions, such
as sleep disturbance and fatigue (Schaakxs, Comijs,
Lamers, Beekman, & Penninx, 2017), while pain and
Journal of Nursing Scholarship, 2018; 50:3, 276–286. 281
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other symptoms have sensory, affective, and functional
dimensions. Care must be taken to elicit relevant dimen-
sions because biomarkers may be differentially related
to various dimensions of these self-reported phenom-
ena, although these possible differences are not yet well
described. Although CDEs for symptom (Redeker et al.,
2015) and self-management science (Moore et al., 2016)
have been identified, further specification is needed to
fully understand how multiple dimensions interact with
biomarkers of interest. Standardization across studies is
also needed to make the most efficacious use of data.
Symptoms also often occur in clusters during everyday
life in individuals suffering with chronic conditions, such
as cancer (Dong, Butow, Costa, Lovell, & Agar, 2014) and
heart disease (Moser et al., 2014). Recent evidence sug-
gests that biomarkers, such as cytokines, are associated
with membership in specific symptom clusters (e.g., Illi
et al., 2012). If a single symptom is actually part of a
cluster, the specificity of the biomarker to one particu-
lar symptom may be compromised. Because symptoms
are also temporal phenomena, with diurnal (Van Onse-
len et al., 2013; Wright et al., 2015) or seasonal rhythms,
these patterns should be accounted for in relation to
biomarkers that may also fluctuate (e.g., salivary corti-
sol). Symptoms also depend upon the context in which
they are perceived. For example, a symptom that may be
considered mild while an individual is interacting with
loved ones may become much more unpleasant or bur-
densome when the individual is alone or in the hospital
(Corwin et al., 2014). A mismatch between the timing
of symptom measurement and the biomarker may also
obscure associations or effects.
Culture (Moser et al., 2014; Park & Johantgen, 2016),
language, reading level, aging, sex, and developmental
level (Schaakxs et al., 2017), among other factors,
influence how symptoms and self-management are
reported and measured (Redeker et al., 2015). Factors
such as aging, race, sex, and gender may also influence
biomarkers, genes, and gene expression. Therefore, these
factors should be considered in analyses and selection
of measures to contextualize findings and minimize
bias.
The causal nature of symptoms and biomarkers must
also be considered and may be bidirectional (Corwin,
Meek, Cook, Lowe, & Sousa, 2012). For example, sleep
disturbance may be either a cause or a consequence
of sympathetic arousal and HPA axis activation; and
limitations in self-management (e.g., inability to exercise
or adhere to medical treatment regimens) may con-
tribute to changes in biological pathways and relevant
biomarkers as well as behavior. These challenges suggest
the ongoing need for experimental and longitudinal
studies to understand causal relationships.
Implications for Future Research and
Use of Biological Common Data
Elements for Symptom and
Self-Management Science
An intended outcome of this third paper in the series
is, as with the previous two, to identify a short list,
minimum set, of CDEs, in this case, biological CDEs, to
be recommended for inclusion in appropriate symptom
and self-management research studies. These recom-
mendations, along with brief measurement guidelines
are presented in Table S2.
The Benefits of Biological Common Data
Elements to Symptom and
Self-Management Science
There are multiple benefits to incorporating biological
CDEs into symptom and self-management science. First,
measuring biological CDEs can provide insights into
the mechanistic underpinnings of patient symptoms,
including symptom clusters. For example, data showing
that IL-6/IL-10 ratios increase over time in patients with
worsening heart failure compared to patients with stable
disease, while at the same time, cognitive deficits and
fatigue increase as well, potentially provide insights into
the mechanisms by which cognitive deficits and fatigue
develop in those patients, that is, that these symptoms
may be driven by a similar increase in the pro- or decrease
in the anti-inflammatory response (Petrovsky, 2001).
Second, when developing an intervention to relieve or
manage a given symptom, investigators often propose a
theoretical or conceptual model that includes a pathway
by which the intervention is hypothesized to work.
When testing the intervention, measuring a biomarker
known to be associated with that pathway before and
after the intervention could provide evidence of both the
efficacy of the intervention and the applicability of the
model (Corwin & Ferranti, 2016). For example, again
considering cognitive deficit and fatigue in heart failure
patients, if a 6-month exercise intervention hypothesized
to improve cognitive function and reduce fatigue by
reducing inflammatory pathways does indeed lead to an
improvement in symptoms compared to baseline and if
that improvement is accompanied by a corresponding
decrease in the IL-6/IL-10 ratio pre- to postintervention,
this would suggest that the intervention is effective and
the proposed model is supported. However, if there is
symptom improvement in the absence of change in the
cytokine ratio, the hypothesized mechanism by which
the intervention is thought to be effective might need
to be reconsidered. Other studies have been published
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recently as well, wherein biomarker status at baseline has
been reported to predict the efficacy of an intervention,
potentially allowing clinicians the ability to identify indi-
viduals up front who might or might not respond to the
intervention in the future. For example, baseline levels
of certain cytokines were identified as predictive of who
would respond to a mindfulness-based stress reduction
intervention and who would not (Reich et al., 2014), and
in a separate study, baseline levels of certain cytokines
were identified as predictive of which patients with
treatment-resistant depression would benefit from the
addition of an anti-inflammatory drug to their standard
depression therapy and who would not (Raison et al.,
2013). These latter examples demonstrate the power of
measuring biomarkers to advance precision health care.
Lastly, and perhaps most importantly, including biologi-
cal CDEs offers the potential for collaboration across nurs-
ing research studies, which in turn will increase sample
size, generalizability of findings, and data reproducibility.
This is especially true if the biological CDEs are used in
conjunction with the previously suggested NINR CDEs
for behavioral symptoms and for research addressing self-
management of chronic conditions. In this way the sci-
entific impact of nursing research will continue to grow,
and patients, families, and communities will benefit.
Clinical Resources
 National Institute of Neurological Disorders and




 National Institute of Nursing Research. Common
data elements at NINR. https://www.ninr.nih.gov/
site-structure/cde-portal
 National Institutes of Health, U.S. National
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